GMKBPharmacogenomics – We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
Clinical Translational Science – One of the challenges hindering genomic implementation is the limited data on the outcomes and cost‐effectiveness of genotype‐guided drug therapy. The IGNITE network, consisting of institutions funded in the network and affiliate members, includes a number of institutions that have implemented pharmacogenetic testing to assist with prescribing decisions.
Cardiovascular Pharmacogenomics – Implications for Patients with Chronic Kidney Disease
Advances in Chronic Kidney Disease – Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease. Thus, patients with CKD often require treatment with cardiovascular drugs, such as antiplatelet, antihypertensive, anticoagulant, and lipid-lowering agents. There is significant inter-patient variability in response to cardiovascular therapies, which contributes to risk for treatment failure or adverse drug effects.
Race, Genomics and Chronic Disease: What Patients with African Ancestry Have to Say
Journal of Health Care for the Poor and Underserved – To translate genomic discoveries into practice, we gathered information about effects and challenges incorporating genetic risk in clinical care.
High-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine
Clinical and Translational Science – In this article, we review high‐throughput assays that have been developed to assess a variety of the functional impacts of the variants.
Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice
Value in Health – Implementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health
Genetic determinants of P2Y12 inhibitors and clinical implications
Interventional Cardiology Clinics- This review describes genetic contributions to variable response to platelet P2Y12 inhibitors, guidelines for selecting antiplatelet therapy based on genotype, and examples of clinical implementation of genotype-guided antiplatelet therapy after PCI.
Medical student preparedness for an era of personalized medicine: findings from one US medical school
Personalized Medicine – The objective of this research was to assess medical student preparedness for the use of personalized medicine.
Pharmacists should jump onto the clinical pharmacogenetics train
American Journal of Public Health – This issue of AJHP is a theme issue on precision medicine, focusing on the use of pharmacogenetics in the clinical setting. The articles included provide substantial insight on how and why pharmacogenetics might and can be implemented in the clinical setting.
Implementation of inpatient models of pharmacogenetics programs
American Journal of Health-System Pharmacy – The operational elements essential for establishing an inpatient pharmacogenetic service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug therapy in pharmacogenetics programs at three institutions is highlighted.